BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that
develops and markets products in the field of regenerative
medicine, today announced that Chief Executive Officer Michael D.
West, PhD will present at the 13th Annual Needham Healthcare
Conference to be held April 8-9, 2014 in New York City.
The following are specific details regarding BioTime’s
presentation:
Event:
13th Annual Needham
Healthcare Conference
Date: Tuesday, April 8, 2014 Time: 1:40 – 2:20 p.m.
EDT Location: The Westin Grand Central Hotel, New York, NY
A live-streaming webcast of the company presentations will be
available at http://wsw.com/webcast/needham65/btx. The webcast will
be archived for 90 days following the live presentation and will
also be available on BioTime's website at www.biotimeinc.com.
About BioTime
BioTime is a biotechnology company engaged in research and
product development in the field of regenerative medicine.
Regenerative medicine refers to therapies based on stem cell
technology that are designed to rebuild cell and tissue function
lost due to degenerative disease or injury. BioTime’s focus is on
pluripotent stem cell technology based on human embryonic stem
(“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and
iPS cells provide a means of manufacturing every cell type in the
human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of
proprietary PureStem® progenitors, HyStem® hydrogels, culture
media, and differentiation kits. BioTime is developing Renevia™ (a
HyStem® product) as a biocompatible, implantable hyaluronan and
collagen-based matrix for cell delivery in human clinical
applications. In addition, BioTime has developed Hextend®, a blood
plasma volume expander for use in surgery, emergency trauma
treatment and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for
research, therapeutic, and diagnostic use through its
subsidiaries:
• Asterias Biotherapeutics, Inc. is a new subsidiary which has
acquired the stem cell assets of Geron Corporation, including
patents and other intellectual property, biological materials,
reagents and equipment for the development of new therapeutic
products for regenerative medicine.
• OncoCyte Corporation is developing products and technologies
to diagnose and treat cancer.
• Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an
Israel-based biotechnology company focused on developing stem
cell-based therapies for retinal and neurological disorders,
including the development of retinal pigment epithelial cells for
the treatment of macular degeneration, and treatments for multiple
sclerosis.
• LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and
distributes GeneCards®, the leading human gene database, as part of
an integrated database suite that also includes the LifeMap
Discovery® database of embryonic development, stem cell research
and regenerative medicine, and MalaCards, the human disease
database.
• ES Cell International Pte Ltd., a Singapore private limited
company, developed clinical and research grade hES cell lines and
plans to market those cell lines and other BioTime research
products in over-seas markets as part of BioTime’s ESI BIO
Division.
• BioTime Asia, Limited, a Hong Kong company, may offer and sell
products for research use for BioTime’s ESI BIO Division.
• OrthoCyte Corporation is developing therapies to treat
orthopedic disorders, diseases and injuries.
• ReCyte Therapeutics, Inc. is developing therapies to treat a
variety of cardiovascular and related ischemic disorders, as well
as products for research using cell reprogramming technology.
Additional information about BioTime can be found on the web at
www.biotimeinc.com.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime's Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com
BioTime, Inc.Judith Segall, 510-521-3390, ext.
301jsegall@biotimemail.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024